CY1114920T1 - Φαρμακευτικη συνθεση που περιεχει λακοσαμιδη και λεβετιρακεταμη με συνεργιστικη αντισπασμωδικη δραση - Google Patents

Φαρμακευτικη συνθεση που περιεχει λακοσαμιδη και λεβετιρακεταμη με συνεργιστικη αντισπασμωδικη δραση

Info

Publication number
CY1114920T1
CY1114920T1 CY20141100167T CY141100167T CY1114920T1 CY 1114920 T1 CY1114920 T1 CY 1114920T1 CY 20141100167 T CY20141100167 T CY 20141100167T CY 141100167 T CY141100167 T CY 141100167T CY 1114920 T1 CY1114920 T1 CY 1114920T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
levetiracetam
composition containing
synthetic antibodies
lacosamide
Prior art date
Application number
CY20141100167T
Other languages
Greek (el)
English (en)
Inventor
Thomas Stöhr
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42738170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114920(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06021470A external-priority patent/EP1920780A1/en
Priority claimed from EP06024241A external-priority patent/EP1925314A1/en
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of CY1114920T1 publication Critical patent/CY1114920T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Mechanical Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20141100167T 2006-06-15 2014-02-28 Φαρμακευτικη συνθεση που περιεχει λακοσαμιδη και λεβετιρακεταμη με συνεργιστικη αντισπασμωδικη δραση CY1114920T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81396706P 2006-06-15 2006-06-15
EP06021470A EP1920780A1 (en) 2006-10-12 2006-10-12 Peptide compounds for the treatment of hyperexcitability disorders
EP06021469 2006-10-12
EP06024241A EP1925314A1 (en) 2006-11-22 2006-11-22 Pharmaceutical composition with synergistic anticonvulsant effect
EP12001535.9A EP2462990B2 (en) 2006-06-15 2007-06-15 Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect

Publications (1)

Publication Number Publication Date
CY1114920T1 true CY1114920T1 (el) 2016-12-14

Family

ID=42738170

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100167T CY1114920T1 (el) 2006-06-15 2014-02-28 Φαρμακευτικη συνθεση που περιεχει λακοσαμιδη και λεβετιρακεταμη με συνεργιστικη αντισπασμωδικη δραση

Country Status (19)

Country Link
US (4) US8735356B2 (enExample)
EP (4) EP2695618B2 (enExample)
JP (3) JP5443981B2 (enExample)
KR (2) KR101518427B1 (enExample)
CN (1) CN102846601B (enExample)
AR (1) AR061476A1 (enExample)
AU (1) AU2007260207B2 (enExample)
BR (1) BRPI0713594A2 (enExample)
CA (1) CA2651679C (enExample)
CY (1) CY1114920T1 (enExample)
DK (1) DK2462990T3 (enExample)
EA (2) EA027836B1 (enExample)
ES (4) ES2531118T5 (enExample)
MX (1) MX2008016000A (enExample)
PL (1) PL2462990T3 (enExample)
PT (1) PT2462990E (enExample)
SI (1) SI2462990T1 (enExample)
TW (1) TWI397417B (enExample)
WO (1) WO2007144195A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
WO2011037833A2 (en) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
WO2015079010A2 (en) * 2013-11-29 2015-06-04 Ucb Pharma Gmbh Pharmaceutical composition comprising lacosamide and levetiracetam
EP2878296A1 (en) * 2013-11-29 2015-06-03 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
CN109999033B (zh) * 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
SMT202200173T1 (it) 2016-06-01 2022-05-12 Athira Pharma Inc Composti
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN116359512A (zh) * 2023-03-08 2023-06-30 南方医科大学南方医院 Crmp3作为癫痫的诊断、治疗、预后分子标志物的应用

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ233728A (en) * 1989-05-19 1993-04-28 Res Corp Technologies Inc Amino acid compounds and pharmaceutical compositions thereof
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (enExample) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
JP4313435B2 (ja) * 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
IL126999A (en) * 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
AU744899B2 (en) * 1997-07-15 2002-03-07 Research Corporation Technologies, Inc. Amino acid derivatives useful to treat stroke
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
BR9814951A (pt) 1997-10-31 2000-10-03 Basf Ag Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9816228D0 (en) 1998-07-24 1998-09-23 Pfizer Ltd Isoquinolines
CA2344057C (en) * 1998-09-15 2008-11-18 Eli Lilly And Company Treatment of persistent pain
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
ATE284223T1 (de) * 1999-08-20 2004-12-15 Ortho Mcneil Pharm Inc Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
EP1137642B1 (en) 1999-09-03 2007-12-05 Actelion Pharmaceuticals Ltd. Bis-sulfonamides
EP1600168A3 (en) * 1999-12-01 2009-09-23 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
EP1160248A1 (en) 2000-05-31 2001-12-05 Pfizer Inc. N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
CA2418455A1 (en) * 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
ES2348646T3 (es) * 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
CA2434495A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
MXPA03008639A (es) 2001-03-27 2005-03-07 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolinas.
CN1520283A (zh) 2001-04-26 2004-08-11 ����˹�ж�-����˹˹������˾ 通过结晶作用控制的压紧性
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
ATE384078T1 (de) 2002-11-18 2008-02-15 Bioprospecting Nb Inc Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7465549B2 (en) * 2002-12-03 2008-12-16 Ucb, S.A. Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)
DE60311875T2 (de) 2002-12-19 2007-08-30 Pharmacia Corp. Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
EP1589959A2 (en) 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
WO2004066987A2 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
CA2542064A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. Tao kinase modulators and methods of use
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
ATE428413T1 (de) 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
JP2005160825A (ja) 2003-12-04 2005-06-23 Satoshi Onishi 非接触ｉｃチップを装着した手術用ガーゼ、及びその管理装置
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006019978A2 (en) * 2004-07-16 2006-02-23 The Regents Of The University Of California Compositions and methods for diagnosis and treatment of epilepsy
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
ATE464044T1 (de) * 2004-09-16 2010-04-15 Janssen Pharmaceutica Nv Verwendung von 2-phenyl-1,2-ethanediol- (di)carbamaten zur behandlung von epileptogenese
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
WO2006079547A2 (en) * 2005-01-28 2006-08-03 Schwarz Pharma Ag Spm 927 for add-on therapy of schizophrenia
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
TW200812574A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
EP2214657A1 (en) * 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions
CN105520924B (zh) * 2008-09-05 2019-04-09 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和抗癫痫药的联合药物
EP2444390B1 (en) * 2010-10-19 2017-02-01 Euticals GmbH Process for producing Lacosamide
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide

Also Published As

Publication number Publication date
ES2450070T5 (es) 2018-05-08
EP2462990A1 (en) 2012-06-13
EP2695618A1 (en) 2014-02-12
US9095557B2 (en) 2015-08-04
AU2007260207B2 (en) 2012-11-08
EA200900020A1 (ru) 2009-06-30
AU2007260207A1 (en) 2007-12-21
AR061476A1 (es) 2008-08-27
JP5898149B2 (ja) 2016-04-06
WO2007144195A3 (en) 2008-09-04
PL2462990T3 (pl) 2014-05-30
JP2009545521A (ja) 2009-12-24
EP2992891B1 (en) 2020-08-05
US20120238614A1 (en) 2012-09-20
ES2450070T3 (es) 2014-03-21
PT2462990E (pt) 2014-04-02
TW200812568A (en) 2008-03-16
JP2016104808A (ja) 2016-06-09
KR20090030308A (ko) 2009-03-24
ES2822904T3 (es) 2021-05-05
EP2037965B1 (en) 2017-08-30
ES2645529T3 (es) 2017-12-05
SI2462990T1 (sl) 2014-04-30
KR20150003925A (ko) 2015-01-09
JP2013237705A (ja) 2013-11-28
MX2008016000A (es) 2009-03-05
JP6158376B2 (ja) 2017-07-05
EP2462990B1 (en) 2014-01-01
US8735356B2 (en) 2014-05-27
CN102846601A (zh) 2013-01-02
CA2651679C (en) 2017-01-03
EA027836B1 (ru) 2017-09-29
ES2531118T5 (es) 2022-06-14
WO2007144195A2 (en) 2007-12-21
CN102846601B (zh) 2015-04-29
EP2695618B1 (en) 2014-09-24
US8828943B2 (en) 2014-09-09
EP2037965A2 (en) 2009-03-25
EA201300702A1 (ru) 2013-10-30
US20140088168A1 (en) 2014-03-27
KR101518427B1 (ko) 2015-05-08
EP2992891A1 (en) 2016-03-09
DK2462990T3 (en) 2014-02-17
EP2462990B2 (en) 2018-04-18
US20100240576A1 (en) 2010-09-23
US9446011B2 (en) 2016-09-20
JP5443981B2 (ja) 2014-03-19
BRPI0713594A2 (pt) 2012-10-30
CA2651679A1 (en) 2007-12-21
TWI397417B (zh) 2013-06-01
EP2695618B2 (en) 2022-05-11
EA019757B1 (ru) 2014-06-30
US20150202184A1 (en) 2015-07-23
ES2531118T3 (es) 2015-03-10

Similar Documents

Publication Publication Date Title
CY1114920T1 (el) Φαρμακευτικη συνθεση που περιεχει λακοσαμιδη και λεβετιρακεταμη με συνεργιστικη αντισπασμωδικη δραση
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
CY1121136T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CY1117817T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CR10433A (es) Compuestos organicos y sus usos
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
EA201100084A1 (ru) Сшиваемая полимерная композиция
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE534378T1 (de) Titrierung von tapentadol
BRPI0709769B8 (pt) implantes biodegradáveis para o tratamento de estados associados à dopamina
TW200602324A (en) Tetrahydro-indazole cannabinoid modulators cross reference to related applications
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения